Inversago Pharma is a clinical stage biopharmaceutical company dedicated to developing therapies for patients suffering from metabolic and fibrotic diseases. The company is the leader in the development of peripherally acting CB1 receptor (CB1r) blocker therapies designed to help patients with complications associated with metabolic and fibrotic diseases.

François Ravenelle

Inversago Pharma

Element Capital engages in global macro investing through a combination of fundamental research and quantitative analysis.

Element Capital

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

JDRF T1D Fund

AQC Capital

Anges Quebec

Genesys Capital

adMare Bio Innovations

Amorchem

Fonds de solidarité FTQ

Forbion Capital Partners

New Enterprise Associates

Amgen Ventures

This #WorldDiabetesDay, know your risk, know your response.
Today and all of November, learn more about diabetes prevention, management and self-care on diabetes.ca

I just heard that the acquisition of Inversago by Novo Nordisk has made the 2023 official finalist roster of the European Lifestars Awards! This is true testament to the strategic fit and the value potential of the deal. Great news I wanted to share this morning:

https://lnkd.in/eFkfbGeT


We have now officially closed the acquisition of Inversago Pharma. With this acquisition, we aim to build on our ability to offer innovative medicines to people living with serious chronic diseases. 
 
A warm welcome to our new colleagues - your expertise and talents are a valuable addition to our team!
 
Learn more about this from our Executive Vice President, Martin Holst Lange here 👇

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

This Canada day, we're highlighting a great Canadian biotech company from the Genesys portfoliol! 🇨🇦 🍁 

Key data captured by Stifel group at the #ada2023 conference, highlighting Inversago Pharma     

- Inversago showed impressive CB1 inverse agonist Ph1 obesity data, fixing historical safety issues associated with the target.

- Inversago showed weight reduction data similar in magnitude to what has been accomplished with GLP-1s. More importantly, CB1R MoA is orthogonal to what others are doing and could be used as an ideal candidate for combination approaches.

- Inversago’s INV-202 4 week weight loss data is impressive in when comparing to other drugs (including GLP-1s).

Just finishing up an exciting #ada2023 where I had the amazing opportunity to present #InversagoPharma’s phase 1B data. It is so exciting to see scientific research lead to potential new treatments, truly from the bench to the bedside! Looking forward to bringing this potential treatment to patients suffering from complications of obesity and diabetes.

Metric
Company Name	Inversago Pharma	Element Capital
Symbol
MSH ID	COM:INVERSAGO	COM:ELEMENTCAPITAL
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance
Industry	Biopharmaceuticals	Investment Management
Country	CA	US
Stage
Employee Count	22
Website	inversago.com	elementcapital.com
LinkedIn	inversago-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:INVERSAGO

Inversago Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue